Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 8 | 2026 | 475 | 1.930 |
Why?
|
| Sarcoma | 6 | 2026 | 219 | 1.670 |
Why?
|
| Osteosarcoma | 6 | 2026 | 276 | 1.300 |
Why?
|
| Rhabdomyosarcoma | 5 | 2026 | 231 | 1.220 |
Why?
|
| Sarcoma, Ewing | 6 | 2026 | 122 | 1.050 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2023 | 51 | 0.910 |
Why?
|
| Mitotane | 1 | 2024 | 2 | 0.840 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2024 | 10 | 0.830 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2024 | 22 | 0.820 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 41 | 0.760 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2024 | 251 | 0.740 |
Why?
|
| Hemangioendothelioma | 1 | 2022 | 24 | 0.710 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2022 | 15 | 0.710 |
Why?
|
| Wilms Tumor | 2 | 2026 | 118 | 0.700 |
Why?
|
| Kidney Neoplasms | 3 | 2026 | 421 | 0.690 |
Why?
|
| MicroRNAs | 3 | 2018 | 889 | 0.680 |
Why?
|
| Neoplasms | 8 | 2026 | 3016 | 0.680 |
Why?
|
| Sarcoma, Kaposi | 1 | 2022 | 129 | 0.640 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 10 | 0.530 |
Why?
|
| Biomarkers, Tumor | 4 | 2026 | 1586 | 0.510 |
Why?
|
| Retinal Neoplasms | 1 | 2018 | 71 | 0.500 |
Why?
|
| Exanthema | 1 | 2017 | 74 | 0.470 |
Why?
|
| Adolescent | 24 | 2026 | 20987 | 0.460 |
Why?
|
| Hepatoblastoma | 1 | 2018 | 204 | 0.440 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 1545 | 0.420 |
Why?
|
| Skin | 1 | 2017 | 545 | 0.410 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1801 | 0.400 |
Why?
|
| Young Adult | 13 | 2026 | 10103 | 0.370 |
Why?
|
| Patient Participation | 3 | 2026 | 254 | 0.370 |
Why?
|
| Oncologists | 2 | 2023 | 32 | 0.360 |
Why?
|
| Decision Making | 3 | 2026 | 726 | 0.330 |
Why?
|
| Liver Neoplasms | 2 | 2018 | 1373 | 0.320 |
Why?
|
| Humans | 37 | 2026 | 131163 | 0.300 |
Why?
|
| Transcriptome | 1 | 2015 | 1103 | 0.270 |
Why?
|
| Child | 18 | 2026 | 26341 | 0.260 |
Why?
|
| Parents | 2 | 2026 | 1128 | 0.260 |
Why?
|
| Cancer Care Facilities | 1 | 2026 | 32 | 0.240 |
Why?
|
| Cyclophosphamide | 3 | 2023 | 428 | 0.230 |
Why?
|
| Female | 21 | 2026 | 70963 | 0.230 |
Why?
|
| Ribonuclease III | 1 | 2026 | 100 | 0.230 |
Why?
|
| Appendiceal Neoplasms | 1 | 2025 | 20 | 0.220 |
Why?
|
| Colectomy | 1 | 2025 | 89 | 0.220 |
Why?
|
| Appendectomy | 1 | 2025 | 88 | 0.220 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2026 | 160 | 0.220 |
Why?
|
| Neuroendocrine Tumors | 1 | 2025 | 70 | 0.210 |
Why?
|
| Trophoblastic Tumor, Placental Site | 1 | 2024 | 1 | 0.210 |
Why?
|
| Bronchial Neoplasms | 1 | 2024 | 15 | 0.210 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2024 | 4 | 0.210 |
Why?
|
| Patient Preference | 1 | 2026 | 151 | 0.200 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2024 | 9 | 0.200 |
Why?
|
| Carcinoid Tumor | 1 | 2024 | 24 | 0.200 |
Why?
|
| Chilblains | 1 | 2023 | 3 | 0.190 |
Why?
|
| Leuprolide | 1 | 2023 | 17 | 0.190 |
Why?
|
| Ovarian Reserve | 1 | 2023 | 15 | 0.190 |
Why?
|
| Lymph Nodes | 1 | 2025 | 357 | 0.190 |
Why?
|
| Uterine Neoplasms | 1 | 2024 | 100 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2026 | 1336 | 0.190 |
Why?
|
| Adult | 11 | 2026 | 31282 | 0.180 |
Why?
|
| Pneumonectomy | 1 | 2024 | 154 | 0.180 |
Why?
|
| Male | 17 | 2026 | 64957 | 0.180 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2022 | 101 | 0.180 |
Why?
|
| Neoplasm Staging | 4 | 2025 | 1287 | 0.170 |
Why?
|
| Molecular Biology | 1 | 2022 | 66 | 0.170 |
Why?
|
| Hormone Replacement Therapy | 1 | 2024 | 187 | 0.170 |
Why?
|
| Prognosis | 4 | 2026 | 4886 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2023 | 245 | 0.170 |
Why?
|
| Doxorubicin | 3 | 2023 | 288 | 0.170 |
Why?
|
| Legislation, Drug | 1 | 2020 | 8 | 0.170 |
Why?
|
| Physicians, Women | 1 | 2021 | 54 | 0.170 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 27 | 0.170 |
Why?
|
| Proton Therapy | 1 | 2022 | 155 | 0.160 |
Why?
|
| Survival Rate | 5 | 2026 | 2114 | 0.160 |
Why?
|
| Pulmonary Artery | 1 | 2024 | 434 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2026 | 1272 | 0.160 |
Why?
|
| Career Choice | 1 | 2021 | 166 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 79 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 124 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2026 | 5196 | 0.150 |
Why?
|
| Child, Preschool | 7 | 2026 | 15110 | 0.150 |
Why?
|
| Fertility Preservation | 1 | 2020 | 62 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2023 | 1246 | 0.140 |
Why?
|
| Genomics | 3 | 2024 | 1621 | 0.140 |
Why?
|
| Endothelial Cells | 1 | 2022 | 523 | 0.140 |
Why?
|
| Epigenomics | 1 | 2019 | 181 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 265 | 0.140 |
Why?
|
| Blueberry Plants | 1 | 2017 | 6 | 0.130 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 83 | 0.130 |
Why?
|
| Infant | 6 | 2026 | 13352 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1129 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 707 | 0.120 |
Why?
|
| Sarcoma, Experimental | 1 | 2015 | 15 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 526 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 722 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 157 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2026 | 17753 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 188 | 0.100 |
Why?
|
| Allografts | 1 | 2015 | 220 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2026 | 905 | 0.100 |
Why?
|
| Surveys and Questionnaires | 4 | 2026 | 4066 | 0.100 |
Why?
|
| ROC Curve | 1 | 2015 | 613 | 0.100 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 218 | 0.090 |
Why?
|
| Vincristine | 2 | 2023 | 187 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1882 | 0.090 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 713 | 0.080 |
Why?
|
| United States | 5 | 2026 | 12072 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2026 | 3829 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 2026 | 0.080 |
Why?
|
| Etoposide | 2 | 2023 | 112 | 0.070 |
Why?
|
| Neuroblastoma | 1 | 2014 | 546 | 0.070 |
Why?
|
| Pediatrics | 1 | 2018 | 1252 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2904 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2015 | 3819 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2026 | 41 | 0.060 |
Why?
|
| Margins of Excision | 1 | 2025 | 60 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2026 | 85 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 1011 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4697 | 0.050 |
Why?
|
| Mice | 3 | 2017 | 18301 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2026 | 775 | 0.050 |
Why?
|
| Europe | 1 | 2025 | 365 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8635 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2025 | 426 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2026 | 373 | 0.050 |
Why?
|
| Cysts | 1 | 2024 | 80 | 0.050 |
Why?
|
| Survivorship | 1 | 2023 | 46 | 0.050 |
Why?
|
| Erythema | 1 | 2023 | 29 | 0.050 |
Why?
|
| Aneurysm, False | 1 | 2024 | 84 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2023 | 46 | 0.050 |
Why?
|
| Protons | 1 | 2022 | 94 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2022 | 216 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2022 | 108 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 58 | 0.040 |
Why?
|
| Counseling | 1 | 2023 | 238 | 0.040 |
Why?
|
| Ovary | 1 | 2024 | 345 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 1071 | 0.040 |
Why?
|
| Pregnancy | 2 | 2024 | 7512 | 0.040 |
Why?
|
| Government Regulation | 1 | 2020 | 44 | 0.040 |
Why?
|
| Survivors | 1 | 2023 | 344 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 158 | 0.040 |
Why?
|
| Animals | 3 | 2017 | 33912 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2024 | 398 | 0.040 |
Why?
|
| Apoptosis | 2 | 2017 | 1827 | 0.040 |
Why?
|
| Placenta | 1 | 2024 | 504 | 0.040 |
Why?
|
| Mutation | 2 | 2026 | 6099 | 0.040 |
Why?
|
| Risk Factors | 2 | 2023 | 11074 | 0.030 |
Why?
|
| Fertility | 1 | 2020 | 260 | 0.030 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2017 | 32 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 919 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2017 | 67 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2024 | 1106 | 0.030 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 57 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2017 | 110 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 299 | 0.030 |
Why?
|
| Phenotype | 1 | 2026 | 4497 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 585 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2065 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 975 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 254 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 106 | 0.030 |
Why?
|
| Caspase 2 | 1 | 2015 | 26 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 308 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 615 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 219 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2014 | 7 | 0.030 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2014 | 12 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 3436 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1535 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 115 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 79 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2015 | 175 | 0.030 |
Why?
|
| Aged | 2 | 2023 | 21025 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 64 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 152 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 136 | 0.030 |
Why?
|
| Middle Aged | 2 | 2026 | 28601 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 353 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 245 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 876 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 743 | 0.020 |
Why?
|
| Homozygote | 1 | 2015 | 533 | 0.020 |
Why?
|
| Quality of Life | 1 | 2023 | 2082 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 825 | 0.020 |
Why?
|
| Cisplatin | 1 | 2014 | 274 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 992 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2022 | 3711 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 653 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2015 | 919 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 2326 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2465 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2023 | 12936 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4738 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 1280 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 4686 | 0.010 |
Why?
|